The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis

Amelle G Ra; Zoe Littlewood; Anne Barton; Brian Keevil; Malcolm McTaggart; Richard B Warren; James Bluett

doi:10.1093/bjd/ljae096

The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis

Amelle G Ra
, Zoe Littlewood
, Anne Barton
, Brian Keevil
, Malcolm McTaggart
, Richard B Warren
, James Bluett

Research output: Contribution to journal › Letter › peer-review

Abstract

Psoriasis is a common inflammatory skin condition affecting approximately 2–3% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.

Original language	English
Pages (from-to)	927-929
Number of pages	3
Journal	The British journal of dermatology
Volume	190
Issue number	6
Early online date	8 Mar 2024
DOIs	https://doi.org/10.1093/bjd/ljae096
Publication status	Published - Jun 2024

Keywords

Humans
Psoriasis/drug therapy
Methotrexate/blood
Medication Adherence/statistics & numerical data
Dermatologic Agents/therapeutic use
Female
Male
Middle Aged
Adult
Aged

Access to Document

10.1093/bjd/ljae096

Cite this

@article{e13b5d43c10f46fd955ecdc020469a7f,

title = "The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis",

abstract = "Psoriasis is a common inflammatory skin condition affecting approximately 2–3\% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50\% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.",

keywords = "Humans, Psoriasis/drug therapy, Methotrexate/blood, Medication Adherence/statistics \& numerical data, Dermatologic Agents/therapeutic use, Female, Male, Middle Aged, Adult, Aged",

author = "Ra, \{Amelle G\} and Zoe Littlewood and Anne Barton and Brian Keevil and Malcolm McTaggart and Warren, \{Richard B\} and James Bluett",

year = "2024",

month = jun,

doi = "10.1093/bjd/ljae096",

language = "English",

volume = "190",

pages = "927--929",

journal = "The British journal of dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis

AU - Ra, Amelle G

AU - Littlewood, Zoe

AU - Barton, Anne

AU - Keevil, Brian

AU - McTaggart, Malcolm

AU - Warren, Richard B

AU - Bluett, James

PY - 2024/6

Y1 - 2024/6

N2 - Psoriasis is a common inflammatory skin condition affecting approximately 2–3% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.

AB - Psoriasis is a common inflammatory skin condition affecting approximately 2–3% of people worldwide. Methotrexate (MTX) is a cheap and effective drug that is often recommended as the first-choice systemic agent for psoriasis. Around 40–50% of patients achieve a good response; however, mechanisms of nonresponse are poorly understood. It is not known whether biochemical MTX adherence in patients with psoriasis is suboptimal and requires intervention. Our aim was to audit biochemical MTX adherence using a sensitive liquid chromatography–tandem mass spectrometry in patients prescribed oral MTX for the treatment of psoriasis at our tertiary dermatology centre. Ethical approval for this audit was not required as confirmed by the Health Research Authority.

KW - Humans

KW - Psoriasis/drug therapy

KW - Methotrexate/blood

KW - Medication Adherence/statistics & numerical data

KW - Dermatologic Agents/therapeutic use

KW - Female

KW - Male

KW - Middle Aged

KW - Adult

KW - Aged

UR - https://www.scopus.com/pages/publications/85193561273

U2 - 10.1093/bjd/ljae096

DO - 10.1093/bjd/ljae096

M3 - Letter

C2 - 38454565

SN - 0007-0963

VL - 190

SP - 927

EP - 929

JO - The British journal of dermatology

JF - The British journal of dermatology

IS - 6

ER -

The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this